secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001683168-25-008624
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma shareholders approve 12x increase in authorized common shares to 300M and equity plan expansion
--------------------------------------------------------------------------------

- Authorized common stock increased from 25M to 300M shares; preferred from 416,667 to 5M shares.
- 2020 Equity Plan shares authorized increased by 114,916 to total 115,061 shares.
- All six director nominees elected: Climaco, Gumulka, Keyes, Charles, Cockroft, Mahery.
- MaloneBailey LLP ratified as independent auditor for FY 2025; say-on-pay approved with annual frequency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316825008624/0001683168-25-008624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316825008624/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-008624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer